R S Raju1, N Coburn1, N Liu2, J M Porter2, S J Seung3, M C Cheung1, N Goyert1, N B Leighl4, J S Hoch5, M E Trudeau1, W K Evans6, K N Dainty7, C C Earle1, N Mittmann8. 1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON; 2. Institute for Clinical Evaluative Sciences, Toronto, ON; 3. Health Outcomes and PharmacoEconomics Research Centre, Sunnybrook Research Institute, Toronto, ON; 4. Princess Margaret Cancer Centre, University Health Network, Toronto, ON; 5. Applied Research in Cancer Control, Cancer Care Ontario, Toronto, ON; 6. McMaster University, Hamilton, ON; 7. Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON; 8. Health Outcomes and PharmacoEconomics Research Centre, Sunnybrook Research Institute, Toronto, ON; ; Department of Pharmacology, University of Toronto, Toronto, ON; ; International Centre for Health Innovation, Richard Ivey School of Business, Western University, London, ON.
Abstract
OBJECTIVE: Administrative data are used to describe the pancreatic cancer (pcc) population. The analysis examines demographic details, incidence, site, survival, and factors influencing mortality in a cohort of individuals diagnosed with pcc. METHODS: Incident cases of pcc diagnosed in Ontario between 1 January 2004 and 31 December 2011 were extracted from the Ontario Cancer Registry. They were linked by encrypted health card number to several administrative databases to obtain demographic and mortality information. Descriptive, bivariate, and survival analyses were conducted. RESULTS: During the period of interest, 9221 new cases of pcc (4548 in men, 4673 in women) were diagnosed, for an age-adjusted standardized annual incidence in the range of 8.6-9.5 per 100,000 population. Mean age at diagnosis was 70.3 ± 12.5 years (standard deviation). Five-year survival was 7.2% (12.8% for those <60 years of age and 3.6% for those >80 years of age). Survival varied by sex, older age, rural residence, lower income, site of involvement in the pancreas, and presence of comorbidity. CONCLUSIONS: The mortality rate in pcc is exceptionally high. With an increasing incidence and a mortality positively associated with age, additional support will be needed for this highly fatal disease as demographics in Ontario continue to trend toward a higher proportion of older individuals.
OBJECTIVE: Administrative data are used to describe the pancreatic cancer (pcc) population. The analysis examines demographic details, incidence, site, survival, and factors influencing mortality in a cohort of individuals diagnosed with pcc. METHODS: Incident cases of pcc diagnosed in Ontario between 1 January 2004 and 31 December 2011 were extracted from the Ontario Cancer Registry. They were linked by encrypted health card number to several administrative databases to obtain demographic and mortality information. Descriptive, bivariate, and survival analyses were conducted. RESULTS: During the period of interest, 9221 new cases of pcc (4548 in men, 4673 in women) were diagnosed, for an age-adjusted standardized annual incidence in the range of 8.6-9.5 per 100,000 population. Mean age at diagnosis was 70.3 ± 12.5 years (standard deviation). Five-year survival was 7.2% (12.8% for those <60 years of age and 3.6% for those >80 years of age). Survival varied by sex, older age, rural residence, lower income, site of involvement in the pancreas, and presence of comorbidity. CONCLUSIONS: The mortality rate in pcc is exceptionally high. With an increasing incidence and a mortality positively associated with age, additional support will be needed for this highly fatal disease as demographics in Ontario continue to trend toward a higher proportion of older individuals.
Entities:
Keywords:
Pancreatic adenocarcinoma; outcomes; population studies; retrospective analyses
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Charbel Sandroussi; Chantelle Brace; Erin D Kennedy; Nancy N Baxter; Steven Gallinger; Alice C Wei Journal: J Gastrointest Surg Date: 2010-06-23 Impact factor: 3.452
Authors: Jeanine M Genkinger; Ruifeng Li; Donna Spiegelman; Kristin E Anderson; Demetrius Albanes; Leif Bergkvist; Leslie Bernstein; Amanda Black; Piet A van den Brandt; Dallas R English; Jo L Freudenheim; Charles S Fuchs; Graham G Giles; Edward Giovannucci; R Alexandra Goldbohm; Pamela L Horn-Ross; Eric J Jacobs; Anita Koushik; Satu Männistö; James R Marshall; Anthony B Miller; Alpa V Patel; Kim Robien; Thomas E Rohan; Catherine Schairer; Rachael Stolzenberg-Solomon; Alicja Wolk; Regina G Ziegler; Stephanie A Smith-Warner Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-12-22 Impact factor: 4.254
Authors: D Bossé; T Ng; C Ahmad; A Alfakeeh; I Alruzug; J Biagi; J Brierley; P Chaudhury; S Cleary; B Colwell; C Cripps; L A Dawson; M Dorreen; E Ferland; P Galiatsatos; S Girard; S Gray; F Halwani; N Kopek; A Mahmud; G Martel; L Robillard; B Samson; M Seal; J Siddiqui; L Sideris; S Snow; M Thirwell; M Vickers; R Goodwin; R Goel; T Hsu; E Tsvetkova; B Ward; T Asmis Journal: Curr Oncol Date: 2016-12-21 Impact factor: 3.677
Authors: João Godinho; Mafalda Casa-Nova; João Moreira-Pinto; Pedro Simões; Francisco Paralta Branco; Luísa Leal-Costa; Ana Faria; Fábio Lopes; José Alberto Teixeira; José Luís Passos-Coelho Journal: Oncologist Date: 2019-10-22
Authors: João Godinho; Mafalda Casa-Nova; João Moreira-Pinto; Pedro Simões; Francisco Paralta Branco; Luísa Leal-Costa; Ana Faria; Fábio Lopes; José Alberto Teixeira; José Luís Passos-Coelho Journal: Oncologist Date: 2019-10-22